STOCK TITAN

Simulations Plus Inc. - SLP STOCK NEWS

Welcome to our dedicated news page for Simulations Plus (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Simulations Plus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Simulations Plus's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.86%
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.57%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
earnings
Simulations Plus Inc.

Nasdaq:SLP

SLP Rankings

SLP Stock Data

821.65M
16.15M
19%
78.66%
5.38%
Computer Systems Design Services
Professional, Scientific, and Technical Services
Link
US
Lancaster

About SLP

simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res